^
    Back
    Association details:
    Biomarker:STK11 mutation
    Cancer:Lung Non-Squamous Non-Small Cell Cancer
    Drug:Tecentriq (atezolizumab) (PD-L1 inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Lung Cancer
    Title:

    Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab

    Published date:
    02/17/2021
    Excerpt:
    Importantly, patients harbored STK11/KEAP1 mutations had a relatively worse OS than wild type both in those receiving atezolizumab and docetaxel (all, P < 0.05). 
    Secondary therapy:
    docetaxel
    DOI:
    10.1016/j.lungcan.2021.02.010
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    IASLC-WCLC 2020
    Title:

    P75.02 - Non-Squamous NSCLC Patients Harbored STK11 or KEAP1 Mutation Showed Insensitivity to any Treatment Including Immunotherapy

    Published date:
    01/12/2021
    Excerpt:
    ...we found that non-squamous NSCLC patients harbored STK11 or KEAP1 mutations had worse OS no matter treated with atezolizumab monotherapy or docetaxel (all, P < 0.001)….Non-squamous NSCLC patients harbored STK11 or KEAP1 mutation were not sensitive to any treatment, suggesting they may be a special subtype.